Zenas BioPharma (NASDAQ:ZBIO) Lowered to Strong Sell Rating by Zacks Research

Zenas BioPharma (NASDAQ:ZBIO) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other research firms have also recently issued reports on ZBIO. Citigroup lowered their price objective on shares of Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating for the company in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Evercore assumed coverage on shares of Zenas BioPharma in a research note on Wednesday, November 26th. They set an “outperform” rating and a $55.00 target price on the stock. Wall Street Zen upgraded shares of Zenas BioPharma from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Wedbush reiterated an “outperform” rating and issued a $45.00 price target on shares of Zenas BioPharma in a research note on Monday, December 22nd. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $44.14.

Zenas BioPharma Stock Performance

Zenas BioPharma stock opened at $23.03 on Tuesday. The company has a quick ratio of 5.66, a current ratio of 5.61 and a debt-to-equity ratio of 0.32. The stock has a market cap of $1.32 billion, a PE ratio of -2.95 and a beta of -1.94. Zenas BioPharma has a 12-month low of $6.11 and a 12-month high of $44.60. The business’s 50-day moving average price is $22.91 and its two-hundred day moving average price is $27.15.

Zenas BioPharma (NASDAQ:ZBIO) last posted its earnings results on Monday, March 16th. The company reported ($4.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

Insider Activity at Zenas BioPharma

In other Zenas BioPharma news, Director Patricia L. Allen acquired 15,700 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was acquired at an average price of $24.85 per share, for a total transaction of $390,145.00. Following the acquisition, the director directly owned 15,700 shares in the company, valued at $390,145. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Leon O. Moulder, Jr. bought 57,000 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were acquired at an average price of $17.96 per share, for a total transaction of $1,023,720.00. Following the completion of the transaction, the chief executive officer owned 423,155 shares in the company, valued at $7,599,863.80. This trade represents a 15.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 202,845 shares of company stock worth $3,747,185 in the last quarter. 16.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Zenas BioPharma

Several large investors have recently modified their holdings of ZBIO. PNC Financial Services Group Inc. lifted its holdings in shares of Zenas BioPharma by 41.2% during the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock worth $89,000 after purchasing an additional 2,679 shares during the period. Geode Capital Management LLC increased its holdings in Zenas BioPharma by 4.6% in the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after purchasing an additional 16,461 shares during the period. Intech Investment Management LLC increased its holdings in Zenas BioPharma by 13.9% in the second quarter. Intech Investment Management LLC now owns 13,206 shares of the company’s stock valued at $128,000 after purchasing an additional 1,607 shares during the period. Rhumbline Advisers raised its position in Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after purchasing an additional 8,207 shares during the last quarter. Finally, Federated Hermes Inc. raised its position in Zenas BioPharma by 60.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock worth $18,041,000 after purchasing an additional 703,838 shares during the last quarter.

Key Zenas BioPharma News

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Company says funding supports continued development of obexelimab — a key clinical program that underpins long‑term value, which helps stabilize investor confidence. Zenas BioPharma Funding Supports Obexelimab Plans
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and kept a $44 price target, signaling strong upside from some sell‑side analysts and supporting bullish expectations. HC Wainwright Rating
• Neutral Sentiment: Citigroup trimmed its price target from $43 to $41 but maintained a “buy” rating — a modest downgrade to upside assumptions but not a change in overall endorsement. Citigroup Price Target Cut
• Neutral Sentiment: Morgan Stanley raised its target to $21 and kept an “equal weight”/Hold stance, reflecting a balanced near‑term view that recognizes pipeline potential but flags commercial and leverage uncertainties. Morgan Stanley / TipRanks Note
• Negative Sentiment: Quarterly results missed materially — Zenas reported EPS of ($4.54) vs. consensus of ($1.22). The magnitude of the miss increases short‑term downside risk and raises questions about near‑term cash burn and execution. Quarterly Earnings Press Release
• Negative Sentiment: New disclosure of an IPO‑related securities class action introduces additional financial and operational risk, which can pressure the stock while litigation remains unresolved. IPO-Related Class Action

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.